{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}],"title":"Grade 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"15"}]}],"title":"Grade 2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Grade 3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Grade 4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Missing/Cannot Assess"}],"denoms":[{"counts":[{"groupId":"OG000","value":"59"}],"units":"Participants"}],"description":"The incidence and severity of graft-versus-host disease (GVHD) will be analyzed and reported descriptively. Clinical manifestations including skin rash, diarrhea, and liver function test abnormalities will be assessed. GVHD will be staged using established clinical grading systems: acute GVHD will be graded according to the modified Glucksberg criteria, and chronic GVHD will be graded using the NIH consensus criteria. These grading systems classify GVHD severity based on organ involvement and clinical symptoms. Higher stages or grades reflect more severe disease and are considered worse outcomes.","groups":[{"description":"REDUCED INTENSITY CONDITIONING: Patients receive fludarabine phosphate IV on days -15 to -12, busulfan IV on days -14 to -13, DLI on day -6, and cyclophosphamide IV on days -3 and -2. Patients also undergo TBI on day -10.\n\nTRANSPLANT: Patients undergo allogeneic PBSCT on day 0.\n\nGVHD PROPHYLAXIS: Patients receive tacrolimus IV on days -1 to 42 followed by taper and mycophenolate mofetil IV BID on days -1 to 28\n\nFludarabine phosphate: Given IV\n\nBusulfan: Given IV\n\nTotal-Body Irradiation: Undergo TBI\n\nTherapeutic Allogeneic Lymphocytes: Undergo DLI\n\nCyclophosphamide: Given IV\n\nAllogeneic Hematopoietic Stem Cell Transplantation: Undergo allogeneic PBSCT\n\nPeripheral Blood Stem Cell Transplantation: Undergo allogeneic PBSCT\n\nTacrolimus: Given IV\n\nMycophenolate Mofetil: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies","id":"OG000","title":"Treatment (RIC and allogeneic PBSCT)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Up to 1 year","title":"Incidence and Degree of Graft Versus Host Disease","type":"SECONDARY","unitOfMeasure":"Participants"}